IOT Innovotech Inc

In the wake of rising concern about increased resistance to antibiotics, perpetuated by the use, and misuse of antibiotics in agriculture, human medicine, and livestock production, Innovotech Inc. (TSX VENTURE:IOT) showed, in a recent trial, that its crop protection product, Agress®, is an effective replacement for standard antibiotic treatments for the control of Fire Blight, a devastating bacterial disease of fruit trees.

Fire Blight, caused by the bacterium Erwinia amylovora, can reduce fruit yield or in the worst cases, cause growers to cut-down or burn infected orchards. Primary control methods for the management of Fire Blight involve spraying orchards with antibiotics such as Streptomycin or Oxytetracycline. However, in many fruit producing regions around the world, the bacteria that cause Fire Blight have developed resistance to these antibiotics. For example, over 40% of fruit trees in Canada's Okanagan Valley have been shown to be infected with Fire Blight organisms that are resistant to Streptomycin.

"When applied once during full bloom, at very low concentrations, Agress® showed comparative if not better results than the antibiotic standards, while exhibiting no toxic effects on plant growth," said Dr. Claudia Nischwitz, Plant Pathology Specialist at Utah State University and Principle Investigator for the trial. "Based on these trial results, not only is Agress® an excellent candidate when considering a replacement for existing antibiotic treatments for Fire Blight, but also when choosing the most effective options to reduce or prevent the devastation caused by this disease, which often results in significant financial losses."

Innovotech and its partner, Syngenta, one of the world's leading crop protection companies, continue to expand the potential treatment uses for Agress®, an environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections. Research efforts for Agress®, a product that is cost competitive with existing treatments, have focused on high priority diseases of "high-value added" crops such as fruits, vegetables and potatoes in addition to pulse crops, including dry beans, dry peas, chickpeas and lentils.

About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.

Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including commercially available products in three market segments; the MBEC Assay(TM), bioFILM PA(TM) and InnovoSCEPT veterinary kits. The MBEC Assay(TM) is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA(TM) is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections, while the InnovoSCEPT veterinary tests are designed to determine the most effective antibiotic treatment for infections in both large and small animals.

Innovotech also has three products in advanced stages of development; InnovoSCEPT human tests have been designed specifically to address antibiotic treatment for human infections, Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections and Sani-Lux(TM) is a light-activated, natural hard surface sanitizer.

Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter:www.twitter.com/innovotech

Facebook:www.facebook.com/innovotech

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts: Innovotech Inc. Ken Boutilier President and CEO (780) 448-0585 ext. 221 (780) 424-0941 (FAX)ken.boutilier@innovotech.ca Innovotech Inc. Amanda Stadel Communications Officer (780) 448-0585 ext. 224 (780) 424-0941 (FAX)amanda.stadel@innovotech.ca